Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar-Apr;24(2):117-127.
doi: 10.5863/1551-6776-24.2.117.

Health Economics and Outcomes of Surfactant Treatments for Respiratory Distress Syndrome Among Preterm Infants in US Level III/IV Neonatal Intensive Care Units

Krishnamurthy Sekar, Daniel Fuentes, Michelle R Krukas-Hampel, Frank R Ernst

Health Economics and Outcomes of Surfactant Treatments for Respiratory Distress Syndrome Among Preterm Infants in US Level III/IV Neonatal Intensive Care Units

Krishnamurthy Sekar et al. J Pediatr Pharmacol Ther. 2019 Mar-Apr.

Abstract

Objective: To compare length of stay (LOS), costs, mechanical ventilation (MV), and mortality in preterm infants treated in the Neonatal Intensive Care Unit (NICU) with beractant (BE), calfactant (CA), and poractant alfa (PA) for Respiratory Distress Syndrome (RDS).

Methods: This study evaluated preterm infants born between 2010 and 2013 with RDS diagnosis, gestational age of 25 to 36 weeks, birthweight of ≥500 g, and age of ≤2 days on first surfactant administration. Multivariable regression was used to evaluate all NICU outcomes.

Results: Of 13,240 infants meeting the study criteria, 4136 (31.2%) received BE, 2502 (18.9%) received CA, and 6602 (49.9%) received PA. Adjusted analyses estimated similar mean LOS (BE 26.7 days, CA 27.8 days, and PA 26.2 days) and hospital costs (BE: $50,929; CA: $50,785; and PA: $50,212). Compared to PA, BE and CA were associated with greater odds of MV use on day 3 (OR = 1.56 and 1.60, respectively) and day 7 (OR = 1.39 and 1.28, respectively; all p < 0.05). Adjusted NICU mortality was significantly higher only with CA vs PA (OR = 1.51; p = 0.015).

Conclusion: Adjusted NICU LOS and costs were similar among BE, CA, and PA. Infants receiving PA were less likely to be on MV at 3 and 7 days, and PA treatment was associated with lower odds of NICU mortality when compared to CA.

Keywords: beractant; calfactant; costs; length of stay; mechanical ventilation; mortality; poractant alfa; respiratory distress syndrome; surfactant.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. At the time of the study, MRK and FRE were employees of Premier Research Services, which contracted with Chiesi USA, the study sponsor to conduct the study; DF was an employee of Chiesi USA. The authors had full access to all the data and take responsibility for the integrity and accuracy of the data analysis.

Figures

Figure 1.
Figure 1.
Attrition diagram. Left panel shows attrition of the total newborn population from January 1, 2010, through December 31, 2013, receiving surfactant within 2 days of birth, treated in a level III or IV NICU, and diagnosed with RDS. Right panel further shows the attrition of these newborns receiving only one surfactant and meeting inclusion criteria for gestational age, birthweight, and born without serious congenital abnormalities and receiving surfactant during the index NICU stay. FDA-approved dosages (based on birthweight): beractant 100 mg/kg (initial and repeat doses); calfactant 105 mg/kg (initial and repeat doses); poractant alfa 200 mg/kg (initial dose), 100 mg/kg (repeat dose).
Figure 2.
Figure 2.
Distribution of gestational age (A) and birthweight (B) intervals plotted against percent of preterm infants for the overall study population.
Figure 3.
Figure 3.
Adjusted clinical outcomes. Forest plot depicts the odds ratio with 95% CI for mechanical ventilation at days 3 and 7 and for mortality. For comparisons that are statistically significant (p < 0.05), an OR of <1.0 favors the first surfactant and an OR of >1.0 favors the second comparator.
See this image and copyright information in PMC

References

    1. Sardesai S, Biniwale M, Wertheimer F et al. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res. 2017;81(1–2):240–248. - PubMed
    1. Respiratory distress syndrome. http://emedicine.medscape.com/article/976034 Accessed February 19, 2019.
    1. Martin R. Prevention and treatment of respiratory distress syndrome in preterm infants. In: Post T, editor. UpToDate. Waltham, MA: UpToDate; Sep 13, 2017. https://www.uptodate.com/contents/prevention-and-treatment-of-respirator... Accessed February 19, 2019.
    1. Preterm Birth: Causes, Consequences, and Prevention. Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes; Behrman RE, Butler AS, editors. Preterm Birth: Causes, Consequences, and Prevention. Washington (DC): National Academies Press (US); 2007. B, Prematurity at Birth: Determinants, Consequences, and Geographic Variation. https://www.ncbi.nlm.nih.gov/books/NBK11386/ Accessed October 21, 2017.
    1. Barfield WD. Levels of neonatal care. Pediatrics. 2012;130(3):587–597. - PubMed

LinkOut - more resources